You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Harvard Business School
McKesson
Dow
Boehringer Ingelheim

Last Updated: February 26, 2020

DrugPatentWatch Database Preview

REQUIP Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which patents cover Requip, and when can generic versions of Requip launch?

Requip is a drug marketed by Glaxosmithkline Llc and is included in two NDAs. There are two patents protecting this drug and nine Paragraph IV challenges.

The generic ingredient in REQUIP is ropinirole hydrochloride. There are fourteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ropinirole hydrochloride profile page.

Drug patent expirations by year for REQUIP
Drug Prices for REQUIP

See drug prices for REQUIP

Drug Sales Revenue Trends for REQUIP

See drug sales revenues for REQUIP

Recent Clinical Trials for REQUIP

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Titan PharmaceuticalsPhase 1/Phase 2
Vanderbilt University Medical CenterPhase 4
Seoul National University HospitalPhase 4

See all REQUIP clinical trials

Recent Litigation for REQUIP

Identify potential future generic entrants

District Court Litigation
Case NameDate
Smith Kline & French Laboratories Limited v. Teva Pharmaceuticals USA Inc.2005-04-06

See all REQUIP litigation

Synonyms for REQUIP
030PYR8953
2H-Indol-2-one, 4-(2-(dipropylamino)ethyl)-1,3-dihydro-
2H-Indol-2-one,4-[2-(dipropylamino)ethyl]-1,3-dihydro-
374R219
4-(2-(Dipropylamino)ethyl)-1,3-dihydro-2H-indol-2-one
4-(2-(dipropylamino)ethyl)indolin-2-one
4-(2-dipropylaminoethyl)-1,3-dihydroindol-2-one
4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one
4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one; 4-[2-(Dipropylamino)ethyl]indoline-2-one; Ropinirole; SKF 101468
4-[2-(dipropylamino)ethyl]-1,3-dihydroindol-2-one
4-[2-(dipropylamino)ethyl]-1.3-dihydro-2H-indol-2-one
4-[2-(dipropylamino)ethyl]-2,3-dihydro-1h-indol-2-one
4-[2-(dipropylamino)ethyl]-3H-indol-2-ol
4-[2-(Dipropylamino)ethyl]2-indolinone
4-[2-(dipropylamino)ethyl]indolin-2-one
91374-20-8 (hydrochloride)
91374-21-9
AB01563044_01
AB01563044_02
AB1004799
AC1L1JLL
AJ-08123
AKOS015843123
AN-15583
API0004095
BC226368
BCP09383
BDBM50020680
BIDD:GT0826
BRD-K15933101-003-01-2
C-33038
C07564
CAS-91374-21-9
CC-34286
CCG-205177
CHEBI:8888
CHEMBL589
CTK8D4279
D08489
DB00268
DSSTox_CID_25195
DSSTox_GSID_45195
DSSTox_RID_80742
DTXSID8045195
FT-0652500
GTPL7295
HMS2093K04
HSDB 8252
I06-0692
L000520
Lopac-R-4152
Lopac0_001101
LS-83890
MCULE-1333778454
MolPort-003-666-598
NCGC00015893-01
NCGC00015893-02
NCGC00015893-03
NCGC00015893-04
NCGC00015893-06
NCGC00096064-01
NCGC00096064-02
NSC-758917
NSC758917
Pharmakon1600-01505178
ReQuip CR
ropinirol
Ropinirol [INN-Spanish]
ropinirole
Ropinirole (USAN/INN)
Ropinirole [INN:BAN]
Ropinirole [USAN:INN:BAN]
Ropinirolum
Ropinirolum [INN-Latin]
Ropitor (TN)
SC-16286
SCHEMBL35212
SK&F 101468
SK&F-101,468
SK&F-101468
SK&F-101468-A
SKF 101468
SKF-101468
SPECTRUM1505178
SR-01000076215-3
STL454344
TC-010119
TL8005859
Tox21_110256
Tox21_110256_1
UHSKFQJFRQCDBE-UHFFFAOYSA-N
UNII-030PYR8953
VA11691
ZINC2041
Paragraph IV (Patent) Challenges for REQUIP
Tradename Dosage Ingredient NDA Submissiondate
REQUIP TABLET;ORAL ropinirole hydrochloride 020658 2005-02-04
REQUIP TABLET;ORAL ropinirole hydrochloride 020658 2004-12-22

US Patents and Regulatory Information for REQUIP

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-001 Sep 19, 1997 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-006 Apr 10, 2009 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-005 Oct 31, 2008 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-005 Sep 19, 1997 AB RX Yes No   Start Trial   Start Trial   Start Trial
Glaxosmithkline Llc REQUIP ropinirole hydrochloride TABLET;ORAL 020658-004 Sep 19, 1997 AB RX Yes No   Start Trial   Start Trial   Start Trial
Glaxosmithkline Llc REQUIP XL ropinirole hydrochloride TABLET, EXTENDED RELEASE;ORAL 022008-002 Jun 13, 2008 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for REQUIP

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Merck
Harvard Business School
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.